CN Stock MarketDetailed Quotes

300347 Hangzhou Tigermed Consulting

Watchlist
  • 53.58
  • +0.98+1.86%
Market Closed Aug 16 15:00 CST
46.34BMarket Cap27.39P/E (TTM)

Hangzhou Tigermed Consulting Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Hangzhou Tigermed Consulting Q2 2024 Estimates Date

Currency：CNYAug 28, 2024

Estimate YoY
Revenue
2.09B
+9.74%
EPS
0.48
--
Analyst Rating
Strong Buy

Aug 18, 2024

Hangzhou Tigermed Consulting Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 2.173B--
--2024/Q2-- / 2.066B--
--2024/Q11.660B / 2.216B--
--2023/Q41.734B / 1.874B--
--2023/Q31.940B / 2.027B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 2.173B--
--2024/Q2-- / 2.066B--
--2024/Q11.660B / 2.216B--
--2023/Q41.734B / 1.874B--
--2023/Q31.940B / 2.027B--

Unlock Free Earnings Estimates

Hangzhou Tigermed Consulting Earnings Reports

  • Hangzhou Tigermed Consulting: 2024 First Quarter Report

    Apr 25 12:00 ET

  • Tiger Pharmaceuticals: 2023 Annual Report

    Mar 28 12:00 ET

  • Tiger Pharmaceuticals: 2023 Annual Report Summary

    Mar 28 12:00 ET

  • Tiger Pharmaceuticals: Report for the third quarter of 2023

    Oct 27, 2023 12:00 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Aug 18, 2024

    Strong Buy

    • Strong Buy

      83.33%

    • Buy

      16.67%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    CN
    Overall
    Symbol
    Latest Price
    % Chg